Latent or persistent reservoirs of HIV infection are thought to give rise to renewed viral replication following cessation of HAART. It is felt that the presence of these reservoirs dictates that patients must remain on antiviral therapy for life. Thus any increased understanding of the biology of latent reservoirs would be quite important. In addition, devising ways to purge latent or persistent reservoirs may hold promise for the treatment of HIV disease. Our laboratory has earlier proposed an "activation/elimination" approach whereby latently infected cells are activated to express virus, and subsequently targeted for destruction by specific anti-HIV immunotoxins. We now have at our disposal several novel synthetic protein kinase (PKC) activators that appear to be quite active in their ability to induce the expression of latent HIV. We are also exploring novel nanoparticle delivery vehicles, which can specifically target activating agents to CD4-bearing cells. In addition, we have found reproducible latent reservoirs in the thymus, blood and spleens of an improved humanized mouse model, the BLT mouse. We will couple these systems to gain a greater understanding of the biology of latent HIV infection. We will also use these systems to develop a strategy to activate latent HIV, in both in vitro and in vivo systems. We will accomplish this through the following Specific Aims: 1) Define and characterize the various viral reservoirs in the BLT mouse model;2) Characterize and optimize novel PKC activators coupled with new delivery methods for stimulating viral reservoirs in vitro and ex vivo;3) Explore the use of novel PKC activators and delivery methods to stimulate latent HIV in BLT mice on HAART. We hope that these studies will provide proof-of-concept that specific activation of viral reservoirs can be accomplished in vivo, and that valuable pre-clinical data regarding this approach will be obtained. If successful, these studies could pave the way for future clinical trials of this type of approach to decrease or eliminate persistent viral reservoirs.
Latent or persistent reservoirs of HIV-1 may be the chief hurdle to eradication of infection, as they harbor integrated virus that can rekindle active infection if therapy is discontinued. This proposal aims to develop methods to attack latent reservoirs by an activation strategy. Knowledge gained could point the way towards improved clinical management of AIDS.
|Buehler, Daniel C; Marsden, Matthew D; Shen, Sean et al. (2014) Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano 8:7723-32|
|Marsden, Matthew D; Zack, Jerome A (2014) Neutralizing the HIV reservoir. Cell 158:971-2|
|Kim, Sohn G; Jung, James B; Dixit, Dhaval et al. (2013) Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection. J Leukoc Biol 94:835-43|
|Beans, Elizabeth J; Fournogerakis, Dennis; Gauntlett, Carolyn et al. (2013) Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A 110:11698-703|
|Nixon, Christopher C; Vatakis, Dimitrios N; Reichelderfer, Scott N et al. (2013) HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 122:2195-204|
|Zack, Jerome A; Kim, Sohn G; Vatakis, Dimitrios N (2013) HIV restriction in quiescent CD4? T cells. Retrovirology 10:37|
|Marsden, Matthew D; Zack, Jerome A (2013) HIV/AIDS eradication. Bioorg Med Chem Lett 23:4003-10|
|Liu, Su-Yang; Aliyari, Roghiyh; Chikere, Kelechi et al. (2013) Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 38:92-105|
|Kitchen, Scott G; Levin, Bernard R; Bristol, Gregory et al. (2012) In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 8:e1002649|
|Marsden, Matthew D; Kovochich, Michael; Suree, Nuttee et al. (2012) HIV latency in the humanized BLT mouse. J Virol 86:339-47|
Showing the most recent 10 out of 19 publications